Recommended regimens and durations (weeks) for patients with compensated cirrhosis who have never been treated, according to HCV genotype*
| Regimen | HCV genotype | ||||||
|---|---|---|---|---|---|---|---|
| 1a | 1b | 2 | 3 | 4 | 5 | 6 | |
| Ledipasvir/sofosbuvir (Harvoni) | 12 wk ± ribavirin† | 12 wk | NR | + ribavirin 12 wk | 12 wk | 12 wk | 12 wk |
| Elbasvir/grazoprevir (Zepatier) | 12–16 wk ± ribavirin† | 12 wk | NR | + sofosbuvir × 12 wk | 12 wk | NR | NR |
| Paritaprevir/ritonavir/ombitasvir + dasabuvir (Holkira Pak) | + RBV 12 wk | 12 wk | NR | NR | Paritaprevir/ritonavir/ombitasvir + ribavirin 12 wk | NR | NR |
| Sofosbuvir + daclatasvir (Sovaldi + Daklinza) | 24 wk | 24 wk | 24 wk | 24 wk ± ribavirin | NR | NR | NR |
| Sofosbuvir/velpatasvir (Epclusa) | 12 wk | 12 wk | 12 wk | 12 wk ± ribavirin‡ | 12 wk | 12 wk | 12 wk |
| Glecaprevir/pibrentasvir (Maviret) | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk | 12 wk |
| Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) | NR | NR | NR | NR | NR | NR | NR |
Note: HCV = hepatitis C virus, NR = not recommended, RBV = ribavirin.
↵* Where indicated, to be dosed according to weight: ≤ 75 kg: 1000 mg daily; ≥ 75 kg: 1200 mg daily. See Appendix 1 for reference supporting recommendations.
↵† Resistance testing suggested for people with genotype 1a infection with compensated cirrhosis before treatment with ledipasvir/sofosbuvir or elbasvir/grazoprevir. If resistance to nonstructural 5A (NS5A) inhibitors is present, treatment should be extended to 16 weeks with the addition of weight-based ribavirin.
↵‡ Resistance testing suggested for people with genotype 3 infection with compensated cirrhosis before treatment with sofosbuvir/velpatasvir. If resistance to NS5A inhibitors is present, addition of weight-based ribavirin may be considered.